Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. Peter C. Enzinger, MD
|
|
Give Review
Dr. Peter C. Enzinger practices Oncology. Doctor Peter C. Enzinger, MD has written publications. He has 54 publications published with PubMed. The lastest publication is: 'Irinotecan and cisplatin in upper gastrointestinal malignancies.' Peter Enzinger accepts Medicare payments and is listed with Medicare.gov.
Publications
- Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma.
- Localized Colon Cancer, Version 3.2013.
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
- Metastatic Colon Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines.
- Feasibility of computer-based self-administered Cancer-specific geriatric assessment in older patients with gastrointestinal malignancy.
- Gastrointestinal Adenocarcinomas of the Esophagus, Stomach, and Colon Exhibit Distinct Patterns of Genome Instability and Oncogenesis.
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors.
- Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer.
- Colon Cancer.
- A phase 2 study of oral MKC-1, an inhibitor of importin-?, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic Cancer.
- A multicenter phase II trial of single-agent cetuximab in advanced Esophageal and gastric adenocarcinoma.
- NCCN clinical practice guidelines in oncology. Anal carcinoma.
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract Cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinica...
- Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancr...
- NCCN Clinical Practice Guidelines in Oncology: rectal Cancer.
- NCCN Clinical Practice Guidelines in Oncology: colon Cancer.
- Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric Cancer.
- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic Cancer.
- O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with Neuroendocrine tumors.
- Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic Cancer.
- Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal Cancer.
- Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
- Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal Cancer.
- CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable coloRectal carcinoma.
- Impact of hospital volume on recurrence and survival after surgery for gastric Cancer.
- Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal Cancer.
- Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid Tumors.
- Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal Cancer.
- Phase II study of recombinant human endostatin in patients with advanced Neuroendocrine tumors.
- A phase II trial of irinotecan and cisplatin in patients with metastatic Neuroendocrine tumors.
- A Phase II trial of vinorelbine in patients with advanced gastroEsophageal adenocarcinoma.
- Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal Cancer.
- Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
- Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal Cancer.
- A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the Stomach or esophagus.
- The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal Cancer.
- Phase II study of temozolomide and thalidomide in patients with metastatic Neuroendocrine tumors.
- A phase II trial of irinotecan in patients with previously untreated advanced Esophageal and gastric adenocarcinoma.
- Assessment of a dietary questionnaire in Cancer patients receiving cytotoxic chemotherapy.
- Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal Cancer.
- A Phase II trial of gemcitabine for metastatic Neuroendocrine tumors.
- Colon Cancer surgeries compared. In patients with certain characteristics, laparoscopically assisted colectomy works well.
- Should people with Barrett's esophagus, who are at risk for Cancer of the esophagus, avoid alcohol?
- Gastrointestinal Cancer in older patients.
- Esophageal Cancer.
- A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal Cancer.
- Irinotecan in esophageal Cancer.
- Chemotherapy in esophageal Cancer.
- Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal Cancer.
- Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced Esophageal carcinoma.
- Irinotecan and cisplatin in upper gastrointestinal Malignancies.
- Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma.
Schools
The Warren Alpert Medical School Of Brown University
Strong Meml Hospital University Rochester
Hospital St Louis
Meml Sloan Kettering Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Hospital
-
Boston Children's Hospital -
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Helpful Reviews
Similar Doctors
|
|
Dr. Elizabeth B. Lamont, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wei Wang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jane C. Weeks, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Donald W. Kufe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam J. Bass, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Meyerhardt, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Bruce J. Dezube, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Kenneth A. Bauer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan Moody, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nageatte Ibrahim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lecia V. Sequist, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gregory A. Abel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy P. Cooley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason S. Fisherman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael R. Cassidy, MD
This Doctor is OpenDoctor Recommended.
|